Epithalon vs MOTS-C
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the pineal extract preparation Epithalamin, and its literature reports telomerase induction, telomere elongation in cultured human cells, circadian and pineal gene expression changes and lifespan extension in flies and rodents. MOTS-c is a 16-amino-acid microprotein encoded inside the mitochondrial 12S ribosomal RNA gene that acts as a retrograde signal from mitochondria to the nucleus, with reported effects on AMPK signalling, insulin sensitivity and exercise capacity. Both are sold as longevity peptides, which is why they are set side by side. No published study has administered or tested them in the same experiment, in any model. A single systematic review of peptide regulation of gene expression describes both, separately, as examples of short peptides that reach the nucleus and alter transcription. Everything else in the comparison is assembled from two literatures that share a theme and nothing else.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published experiment has administered or tested Epithalon and MOTS-c together, in cell culture, in an animal model or in humans. Searches of PubMed field indexes and of Europe PMC returned exactly one record that engages both: a 2021 systematic review from the St Petersburg group led by Khavinson, which surveys short peptides that regulate gene expression. That review describes the AEDG tetrapeptide among peptides reported to modulate neuro-immuno-endocrine function, circadian rhythm and antioxidant defence, and separately describes MOTS-c as a mitochondrially encoded peptide that translocates into the nucleus under metabolic stress and activates nuclear antioxidant response genes. The two appear as parallel illustrations of the same general idea rather than as compared interventions, and the authors administered nothing. Any comparison drawn between them is therefore indirect, built from separate studies conducted in different species, on different endpoints, by research communities that do not cite each other.
The publication that covers both
- 01Systematic review2021
Peptide Regulation of Gene Expression: A Systematic Review.
Khavinson VK, et al. · Molecules · systematic review of short peptides reported to regulate gene expression, covering polyfunctional peptides including AEDG and mitochondrially derived peptides
The review listed the AEDG tetrapeptide, Epitalon, among polyfunctional short peptides reported to regulate neuro-immuno-endocrine function, circadian rhythm, retinal protection, antioxidant activity, geroprotection and fibroblast differentiation. In a separate passage it described MOTS-c as a peptide encoded by the mitochondrial genome that, under metabolic stress such as glucose deprivation, transfers into the cell nucleus and activates the expression of nuclear antioxidant response genes, and grouped it with humanin as a mitochondrially derived peptide whose synthesis falls in senescence. The two were presented as separate examples within a shared framework; neither was administered and no comparison was made.
Side by side.
| Epithalon | MOTS-C | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the pineal gland extract preparation Epithalamin. It is a laboratory construct modelled on an extract rather than a molecule with a mapped gene. | A 16-amino-acid microprotein encoded within the mitochondrial 12S ribosomal RNA gene and translated from mitochondrial DNA, with a coding-region variant, m.1382A>C (K14Q), identified in human populations. |
| Mechanism as described in the literature | Published work reports induction of telomerase activity and telomere elongation in cultured human cells, modulation of circadian and pineal gene expression, chromatin decondensation in aged cells and antioxidant effects. | Described as a retrograde mitochondrial-to-nuclear signal that activates AMPK, engages folate-methionine one-carbon metabolism and, under metabolic stress, translocates to the nucleus to regulate stress-response and antioxidant gene expression. |
| Size of the evidence base | Fifteen verified studies in this library, of which eight are in vitro, three are animal in vivo, two are human and two are reviews. The great majority of the underlying corpus originates from a single Russian research group. | Fifteen verified studies, of which seven are human observational, six are animal in vivo, one is a systematic review and one a narrative review. The work comes from multiple independent groups across several countries. |
| Best-characterised finding | Induction of telomerase activity and telomere elongation in human somatic cells, first reported in 2003 and reproduced in an independent 2025 cell-line study that attributed the effect to telomerase upregulation or alternative lengthening of telomeres. | Improved insulin sensitivity, mitochondrial respiration and exercise capacity in rodents given the peptide, together with an exercise-induced rise in endogenous MOTS-c and a reported role in age-dependent physical decline and muscle homeostasis. |
| Human data | Two human records: a buccal epithelium study of cellular ageing marker proteins, and a long-running open, non-randomised report on pineal and thymic peptide preparations. No registered, placebo-controlled randomised trial of the synthetic tetrapeptide has been published in the indexed literature. | Observational and genetic only. Circulating MOTS-c has been measured as a candidate biomarker in metabolic, cardiovascular, renal and reproductive conditions, and a mitochondrial variant has been associated with type 2 diabetes risk in East Asian men. No controlled trial has administered exogenous MOTS-c to humans. |
| Independent replication | Limited. The corpus is dominated by the St Petersburg Institute of Bioregulation and Gerontology and is largely published in Russian-language journals; the small number of independent papers are in vitro only, appearing between 2022 and 2025. | Present. The original 2015 description and subsequent muscle, islet and training studies come from separate laboratories, and the human biomarker work spans multiple unrelated cohorts. |
| Consistency of the recent signal | Recent in vitro work has been broadly consistent with the older claims on telomerase and antioxidant endpoints, though it remains cell culture rather than controlled human research. | Inconsistent as a biomarker: circulating MOTS-c has moved in opposite directions across conditions, reported lower in diabetes and higher in obesity and acute coronary syndrome, with assay standardisation differing between studies. |
| Basis of most marketing claims | Extrapolation from telomerase induction in cultured cells and rodent lifespan data to human ageing, without any randomised human trial and without characterised human pharmacokinetics or long-term safety, including any oncological risk from telomerase induction. | Extrapolation from rodent administration studies and from human biomarker associations to an injected product, when no human has been given exogenous MOTS-c in a published controlled trial. |
And what it does not.
Nothing in the published literature establishes how these two peptides compare, because no experiment has tested them together. Both are marketed on the same premise, that a short peptide can slow biological ageing, and both fall short of it in different ways. Epithalon has the longer record and the more specific claim, telomerase induction and telomere elongation, but that record is concentrated in one research group, largely published in Russian-language journals, and contains no registered placebo-controlled trial of the synthetic tetrapeptide; the human longevity reports used a pineal extract under open designs. MOTS-c has broader independent replication and a genuine mitochondrial gene behind it, but every interventional result is rodent or cell culture, the human data are biomarker associations that point in opposite directions across conditions, and no controlled trial has ever administered the peptide to a person. Neither has established human pharmacokinetics, dose-response or long-term safety, and the one review that names both simply describes each in turn.
Common questions.
- Has any study compared Epithalon and MOTS-c directly?
No. Searches of PubMed and Europe PMC returned no experiment that administered or tested both, in cell culture, in animals or in people. The single record that engages both is a 2021 systematic review of peptide regulation of gene expression, which describes the AEDG tetrapeptide and MOTS-c in separate passages as examples of short peptides that influence transcription. The review conducted no experiment, and the two research communities do not otherwise cite one another.
- Is MOTS-c an endogenous molecule in a way Epithalon is not?
Yes, and the distinction is real. MOTS-c is translated from an open reading frame inside the mitochondrial 12S ribosomal RNA gene, is measurable in human circulation, rises with exercise, and carries a described coding variant associated with type 2 diabetes risk in one population. Epithalon is a synthetic tetrapeptide modelled on a pineal gland extract; it is not described in the literature as an endogenous human peptide with its own gene.
- Which of the two has been given to humans in a published trial?
Neither has a registered, placebo-controlled randomised trial. Epithalon has two human records in this library, a buccal epithelium marker study and an open, non-randomised report on pineal and thymic peptide preparations in which the preparation used was the extract rather than the synthetic tetrapeptide. MOTS-c has no interventional human data at all; its human literature consists of observational biomarker measurements and one mitochondrial genotype association study.
- Why do MOTS-c blood levels move in opposite directions across studies?
Published cohorts have reported lower circulating MOTS-c in diabetes and higher levels in obesity and in acute coronary syndrome, and levels have also been reported to change with heat stress, immobilisation and endurance exercise. Assay standardisation differs between studies, which complicates comparison. The consequence is that MOTS-c is not a settled marker: the direction of change appears to depend on the condition and possibly on the measurement method rather than tracking a single underlying process.
- Does telomerase induction make Epithalon the stronger longevity candidate?
It makes it the more specific claim, not the better-supported one. Telomerase activity and telomere elongation after Epitalon exposure have been reported in human somatic cells and reproduced independently in cell lines in 2025. Those are in vitro findings, and the research entry for the compound records that human pharmacokinetics, dose-response and long-term safety remain uncharacterised, including any oncological risk that telomerase induction might carry. No human outcome trial has tested whether the mechanism translates.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.